

PURPOSE OF BILL: HB 1321

To regulate step therapy and fail first protocols concerning certain prescribed ventilators.

ACTUARIAL STATEMENT

The Fiscal Impact Statement was prepared according to generally accepted actuarial principles and practices, in compliance with ACT 112. The Statement provides an estimate of the financial and actuarial effect of the proposed change(s) on the Plans, if possible. The Statement makes no comment or opinion with regard to the merits of the measure for which the Statement is prepared; however, any identified technical or mechanical defects have been noted.

We have reviewed the input and results of our analysis for reasonableness and relied upon the data and information provided by the Plans and their Claims Processing Contractors.

A handwritten signature in black ink, appearing to read "Patrick Klein".

3/12/2025

Patrick Klein, FSA, MAAA
Vice President, Segal

Date

A handwritten signature in black ink, appearing to read "Matthew Kersting".

3/12/2025

Matthew Kersting, FSA, MAAA
Vice President, Segal

Date

PROJECTED COSTS

Plan	Plan Design Change	Estimated Cost/(Savings)
EBD	No Change	No Impact

PRICING APPROACH AND COMMENTS

House Bill 1321 prohibits step therapy and fail first protocols of a lesser device or healthcare service for a prescription or order of a healthcare professional for a noninvasive ventilator.

Non-invasive home mechanical ventilators are currently covered for EBD members with COPD who meet certain criteria. EBD's plan has no step therapy or fail-first requirements for qualifying members. Therefore, HB 1321 should have no financial impact on the plan.